Salix Pharmaceuticals (SLXP) 103.36 $SLXP
SECURITIES ALERT: Rosen Law Firm Reminds Salix Pharmaceuticals, Ltd. Shareholders of Important Deadline in Class Action -- SLXP
GlobeNewswire - Thu Dec 11, 4:50PM CST
The Rosen Law Firm reminds purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014, of the important January 6, 2015 lead plaintiff deadline in the class action.
SLXP: 103.36 (-2.79)
Can Salix Pharmaceuticals (SLXP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 7:58AM CST
The positive earnings estimate revisions suggest that analysts are becoming more optimistic on SLXP’s earnings for the coming quarter and year
SLXP: 103.36 (-2.79)
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 104.43 (-2.29), SHPG: 213.70 (-0.41), SLXP: 103.36 (-2.79)
Lieff Cabraser Reminds Salix Pharmaceuticals, Inc. Investors of Upcoming Deadline in Class Action Litigation - SLXP
Business Wire - Wed Dec 10, 6:48PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the January 6, 2015 deadline to move for appointment as lead plaintiff in the securities class action litigation brought on behalf of investors who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc. ("Salix"
(NasdaqGS: SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 103.36 (-2.79)
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 2:30PM CST
Ironwood Pharmaceuticals, Inc. (IRWD) started dosing patients in a phase IIa study on IW-9179 for the relief from symptoms associated with diabetic gastroparesis.
LCI: 43.58 (-0.46), ACT: 259.00 (-4.00), IRWD: 15.00 (+0.09), SLXP: 103.36 (-2.79)
SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015
Business Wire - Tue Dec 09, 11:01AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NasdaqGS:SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 103.36 (-2.79)
Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. and of the Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Tue Dec 09, 9:39AM CST
Morgan & Morgan reminds investors that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company" (Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 103.36 (-2.79)
Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST
SGYP: 2.93 (-0.05), PGNX: 7.10 (+0.16), CBST: 96.31 (+0.04), AZN: 71.80 (-1.80), SLXP: 103.36 (-2.79), NKTR: 15.31 (-0.29)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Salix Pharmaceuticals, Ltd. to Contact Brower Piven Before the January 6, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SLXP
GlobeNewswire - Fri Dec 05, 8:20PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (Nasdaq:SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff.
SLXP: 103.36 (-2.79)
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:03AM CST
SLXP data by YCharts What: Shares of Salix Pharmaceuticals , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P...
SLXP: 103.36 (-2.79)
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
at The Street - Thu Dec 04, 7:31PM CST
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
KMI: 39.17 (-0.71), RH: 93.59 (-0.40), BIIB: 344.49 (+2.16), GD: 137.41 (-4.99), GE: 24.89 (-0.52), CAG: 36.73 (-0.56), STKL: 11.04 (-0.29), VTR: 74.44 (+0.77), TWX: 82.12 (-1.19), SBUX: 83.25 (+0.13), YHOO: 50.24 (+0.30), T: 32.16 (-0.55), IDT: 18.09 (-0.33), COST: 137.88 (-3.53), DG: 69.80 (+0.65), GOOGL: 521.51 (-10.60), TRAK: 44.56 (-0.35), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01), AMZN: 307.32 (-0.04), GPRO: 60.52 (+0.47), HD: 99.78 (-0.49), DRE: 19.30 (-0.27), PLUG: 2.93 (-0.17), ALU: 3.35 (-0.08), FB: 77.83 (+0.10), SLXP: 103.36 (-2.79), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HABT: 41.89 (+0.55), FCAU: 11.36 (+0.18), BMY: 58.75 (-0.93), HPQ: 38.01 (-0.46), GTLS: 32.52 (-2.45), CELG: 114.49 (-2.25), UA: 68.83 (+0.30), BTU: 7.37 (-0.04), LB: 83.39 (+0.24), ESV: 27.04 (-0.80), GILD: 104.13 (-0.18), VALE: 7.19 (-0.07), TXN: 53.11 (-1.38), MRO: 25.45 (-0.80), BAS: 5.22 (+0.05), CVX: 102.38 (-2.53), BABA: 105.11 (+0.14)
Salix Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.65%
Comtex SmarTrend(R) - Tue Dec 02, 4:15PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $101.75 to a high of $104.97. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $104.21 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 103.36 (-2.79)
SLXP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
PR Newswire - Tue Dec 02, 11:35AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NasdaqGS: SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 103.36 (-2.79)
Hagens Berman Reminds Investors of January 6th Lead Plaintiff Deadline in Suit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Mon Dec 01, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors of the upcoming Lead Plaintiff deadline in the lawsuit filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company" . The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff.
SLXP: 103.36 (-2.79)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Salix Pharmaceuticals of Class Action Lawsuit and Upcoming Deadline -- SLXP
GlobeNewswire - Fri Nov 28, 2:00AM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company" (Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
SLXP: 103.36 (-2.79)
Pharming Reports on Financial Results for the First Nine Months of 2014
PR Newswire Europe - Wed Nov 26, 8:17PM CST
LEIDEN, The Netherlands, October 30, 2014 /PRNewswire/ --
SLXP: 103.36 (-2.79)
Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
PR Newswire Europe - Wed Nov 26, 12:16PM CST
LEIDEN, The Netherlands, October 13, 2014 /PRNewswire/ --
SLXP: 103.36 (-2.79)
INVESTOR ALERT: Class Action Lawsuit Against Salix Pharmaceuticals, Ltd. Announced by Law Offices of Howard G. Smith
Business Wire - Wed Nov 26, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who have losses of $250,000 or more are encouraged to contact the firm for more information.
SLXP: 103.36 (-2.79)
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Salix Pharmaceuticals, Ltd. - SLXP
GlobeNewswire - Tue Nov 25, 4:00PM CST
The Rosen Law Firm announces a class action lawsuit was filed on behalf of purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014. The lawsuit seeks to recover damages for Salix investors under the federal securities laws.
SLXP: 103.36 (-2.79)
Salix Pharmaceuticals Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Tue Nov 25, 9:57AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. ("Salix" or "Company" (NasdaqGS: SLXP) and several officers and directors for acts taken during the period of November 8, 2013 to November 6, 2014 (the "Class Period" .
SLXP: 103.36 (-2.79)
SECURITIES ALERT: Rosen Law Firm Reminds Salix Pharmaceuticals, Ltd. Shareholders of Important Deadline in Class Action -- SLXP
GlobeNewswire - Thu Dec 11, 4:50PM CST
The Rosen Law Firm reminds purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014, of the important January 6, 2015 lead plaintiff deadline in the class action.
SLXP: 103.36 (-2.79)
Can Salix Pharmaceuticals (SLXP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 7:58AM CST
The positive earnings estimate revisions suggest that analysts are becoming more optimistic on SLXP’s earnings for the coming quarter and year
SLXP: 103.36 (-2.79)
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 104.43 (-2.29), SHPG: 213.70 (-0.41), SLXP: 103.36 (-2.79)
Lieff Cabraser Reminds Salix Pharmaceuticals, Inc. Investors of Upcoming Deadline in Class Action Litigation - SLXP
Business Wire - Wed Dec 10, 6:48PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the January 6, 2015 deadline to move for appointment as lead plaintiff in the securities class action litigation brought on behalf of investors who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc. ("Salix"
(NasdaqGS: SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . SLXP: 103.36 (-2.79)
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 2:30PM CST
Ironwood Pharmaceuticals, Inc. (IRWD) started dosing patients in a phase IIa study on IW-9179 for the relief from symptoms associated with diabetic gastroparesis.
LCI: 43.58 (-0.46), ACT: 259.00 (-4.00), IRWD: 15.00 (+0.09), SLXP: 103.36 (-2.79)
SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015
Business Wire - Tue Dec 09, 11:01AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(NasdaqGS:SLXP) securities between November 8, 2013 and November 6, 2014. SLXP: 103.36 (-2.79)
Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. and of the Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Tue Dec 09, 9:39AM CST
Morgan & Morgan reminds investors that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" . SLXP: 103.36 (-2.79)
Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST
SGYP: 2.93 (-0.05), PGNX: 7.10 (+0.16), CBST: 96.31 (+0.04), AZN: 71.80 (-1.80), SLXP: 103.36 (-2.79), NKTR: 15.31 (-0.29)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Salix Pharmaceuticals, Ltd. to Contact Brower Piven Before the January 6, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SLXP
GlobeNewswire - Fri Dec 05, 8:20PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff. SLXP: 103.36 (-2.79)
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:03AM CST
SLXP data by YCharts What: Shares of Salix Pharmaceuticals , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P...
SLXP: 103.36 (-2.79)
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
at The Street - Thu Dec 04, 7:31PM CST
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
KMI: 39.17 (-0.71), RH: 93.59 (-0.40), BIIB: 344.49 (+2.16), GD: 137.41 (-4.99), GE: 24.89 (-0.52), CAG: 36.73 (-0.56), STKL: 11.04 (-0.29), VTR: 74.44 (+0.77), TWX: 82.12 (-1.19), SBUX: 83.25 (+0.13), YHOO: 50.24 (+0.30), T: 32.16 (-0.55), IDT: 18.09 (-0.33), COST: 137.88 (-3.53), DG: 69.80 (+0.65), GOOGL: 521.51 (-10.60), TRAK: 44.56 (-0.35), REGN: 416.44 (-7.91), HTA: 13.06 (+0.01), AMZN: 307.32 (-0.04), GPRO: 60.52 (+0.47), HD: 99.78 (-0.49), DRE: 19.30 (-0.27), PLUG: 2.93 (-0.17), ALU: 3.35 (-0.08), FB: 77.83 (+0.10), SLXP: 103.36 (-2.79), TAP: 72.37 (-2.42), STZ: 90.78 (-1.68), HABT: 41.89 (+0.55), FCAU: 11.36 (+0.18), BMY: 58.75 (-0.93), HPQ: 38.01 (-0.46), GTLS: 32.52 (-2.45), CELG: 114.49 (-2.25), UA: 68.83 (+0.30), BTU: 7.37 (-0.04), LB: 83.39 (+0.24), ESV: 27.04 (-0.80), GILD: 104.13 (-0.18), VALE: 7.19 (-0.07), TXN: 53.11 (-1.38), MRO: 25.45 (-0.80), BAS: 5.22 (+0.05), CVX: 102.38 (-2.53), BABA: 105.11 (+0.14)
Salix Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.65%
Comtex SmarTrend(R) - Tue Dec 02, 4:15PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $101.75 to a high of $104.97. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $104.21 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 103.36 (-2.79)
SLXP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
PR Newswire - Tue Dec 02, 11:35AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(NasdaqGS: SLXP) securities between November 8, 2013 and November 6, 2014. SLXP: 103.36 (-2.79)
Hagens Berman Reminds Investors of January 6th Lead Plaintiff Deadline in Suit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Mon Dec 01, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors of the upcoming Lead Plaintiff deadline in the lawsuit filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company"
. The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff. SLXP: 103.36 (-2.79)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Salix Pharmaceuticals of Class Action Lawsuit and Upcoming Deadline -- SLXP
GlobeNewswire - Fri Nov 28, 2:00AM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company"
(Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . SLXP: 103.36 (-2.79)
Pharming Reports on Financial Results for the First Nine Months of 2014
PR Newswire Europe - Wed Nov 26, 8:17PM CST
LEIDEN, The Netherlands, October 30, 2014 /PRNewswire/ --
SLXP: 103.36 (-2.79)
Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
PR Newswire Europe - Wed Nov 26, 12:16PM CST
LEIDEN, The Netherlands, October 13, 2014 /PRNewswire/ --
SLXP: 103.36 (-2.79)
INVESTOR ALERT: Class Action Lawsuit Against Salix Pharmaceuticals, Ltd. Announced by Law Offices of Howard G. Smith
Business Wire - Wed Nov 26, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who have losses of $250,000 or more are encouraged to contact the firm for more information. SLXP: 103.36 (-2.79)
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Salix Pharmaceuticals, Ltd. - SLXP
GlobeNewswire - Tue Nov 25, 4:00PM CST
The Rosen Law Firm announces a class action lawsuit was filed on behalf of purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014. The lawsuit seeks to recover damages for Salix investors under the federal securities laws.
SLXP: 103.36 (-2.79)
Salix Pharmaceuticals Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Tue Nov 25, 9:57AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. ("Salix" or "Company"
(NasdaqGS: SLXP) and several officers and directors for acts taken during the period of November 8, 2013 to November 6, 2014 (the "Class Period" . SLXP: 103.36 (-2.79)
